Abstract:
Various exemplary metadirectories, systems and/or methods include or allow for executing a software module on an execution engine, emitting semantic information based on the executing, and analyzing the executing using the semantic information. An exemplary execution engine includes an input for receiving software modules, an output for emitting semantic information, and an output for outputting generated output information. Upon execution, an exemplary software module may cause processing of information in a metadirectory and emitting of semantic information pertaining to the processing. Various exemplary metadirectories, systems and/or methods emit and/or store semantic information in a self-defining language, an extensible language, and/or a markup language. Other exemplary metadirectories, systems, and/or methods are also disclosed.
Abstract:
Disclosed are compounds of formulae (I) and (II) that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.
Abstract:
A method of extracting key frames from a video sequence, which video sequence comprises MPEG compressed video data having block motion vectors. The method initially partially decompresses (202) the MPEG compressed video data to obtain block motion vectors and converts (204) the block motion vectors to forward block motion vectors. The method then generates (206) global motion signals and generates (306) dominant global direction clusters. The method then selects (402,404,406) potential key frames of the video sequence using the generated dominant global direction clusters. The method lastly decompresses (408) the selected key frames to obtain the extracted key frames.
Abstract:
Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Abstract:
Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed is a method for promoting extracellular expression of proteins in B. subtilis using cutinase, which belongs to the technical fields of genetic engineering, enzyme engineering and microbial engineering. It teaches co-expressing a cutinase mutant and a target protein in B. subtilis to promote extracellular expression of the target protein which is naturally located inside cells. The target protein includes xylose isomerase, 4,6-α-glucosyltransferase, 4-α-glucosyltransferase, trehalose synthase, branching enzyme and the like. The invention can achieve extracellular expression of intracellularly localized target protein, improve the production efficiency, reduce the production cost and simplify the subsequent extraction process.